DAY 1

Sunday 28 November

  • 17:00-20:00 Welcome addresses
    Awards Ceremony
    OPENING LECTURE Chair: M. Neumaier (Germany)
    Where, when, and how? The quest for Extraterrestrial Life – W. Duschl (Germany)
  • 19:00 Welcome Cocktail
  • 20:00 Concert
    free of charge for participants
    The Munich Convention Bureau is happy to present you a true Bavarian experience. Enjoy a fantastic show introducing you to the Bavarian culture with typical music and dances. Watch out for the whip crackers showing their talents with the whips and listen to the deep sounds
    of the alpine horns.

DAY 2

Monday, 29 November

  • 9:00-10:00 PLENARY LECTURE
    Chair: K. Adeli (Canada)
    Towards next generation diagnostics by X-omics – A. Van Gool (Netherlands)
  • 10:00-10:30 Break
  • 10:30-12:30 SYMPOSIUM 1
    Acute Kidney Injury biomarkers: from lab to bedside – Chairs: C. Ronco (Italy), F. Alcantara (Brazil)
    The continuum of AKI and the utility of biomarkers – C. Ronco (Italy)
    New Biomarkers in AKI: application in clinical routine – L- Forni (UK)
    Prevention/protection of the kidney guided by biomarkers – A. Zarbock (Germany)
    Two oral communications selected among participants’ abstracts
  • 10:30-12:30 SYMPOSIUM 2
    Chronic myeloproliferative neoplasms – Chairs: D. Coriu (Romania), S.N. Constantinescu (Belgium)
    Diagnostic algorithm in myeloproliferative neoplasms – D. Coriu (Romania)
    Inhibiting pathologic signaling induced by driver and epigenetic mutations in myeloproliferative neoplasms: monitoring treatment by next generation sequencing – S.N. Constantinescu (Belgium)
    Challenges of using next-generation sequencing technologies in the clinical management of myeloproliferative neoplasms – C. Mambet (Romania)
    Two oral communications selected among participants’ abstracts
  • 10:30-12:30 SYMPOSIUM 3
    Performance Specifications in Laboratory Medicine – from different models to practical use – Chairs: S. Sandberg (Norway), A. R. Horvath (Australia)
    Analytical performance specifications: From models to practical use – S. Sandberg (Norway)
    Outcome-based models – a link between clinical and analytical performance – A.R. Horvath (Australia)
    A practical way of calculating measurement uncertainty in laboratory medicine and compare it to APS – A. Coskun (Turkey)
    Two oral communications selected among participants’ abstracts
  • 10:30-12:30 SYMPOSIUM 4
    The impact of Artificial Intelligence in diagnostic imaging: perspectives for Laboratory Medicine – Chair: M. Fuchsjäger (Austria), M. Neumaier (Germany)
    Speakers and titles to be announced
  • 10:30-12:30 SYMPOSIUM 5
    COVID-19: biology, clinics, laboratory diagnostics and biosafety issues – Chairs: G. Lippi (Italy), S. Sethi (Singapore)
    Biology and clinics of COVID-19 – G. Lippi (Italy)
    Molecular and serological testing of COVID-19 – K. Adeli (Canada)
    Laboratory responsiveness to COVID-19: results of an IFCC survey – L. Tze Ping (Singapore)
    Clinical laboratory testing in a pandemic: what we have learned from the COVID-19 experience – D. Koch (USA)
  • 10:30-12:30 DGKL SYMPOSIUM
    Metabolomics via NMR spectroscopy – Chairs: M. Nauck (Germany), C. Sina (Germany)
    Lipoprotein diagnostics via NMR. From research to clinical application – M. Nauck (Germany)
    NMR Metabolomics: an enabler of precision nutritio – C. Sina (Germany)
    NMR Biomarker Research: Targeted and untargeted approach – A. Petersmann (Germany)
    Two oral communications selected among participants’ abstracts
  • 12:30-14:00 POSTER SESSION
  • 14:00-16:00 SYMPOSIUM 6
    Artificial intelligence, data science and laboratory medicine: crossed destinies – Chairs: D. Gruson (France), M. Cowie (UK)
    The AI data wave, seizing opportunities – M. Cowie (UK)
    Can collaborations drive successful AI? – K. Selig (Germany)
    How to dive into large scale dataset? – D. Bzdok (Germany)
    What are the keys for Europe as a space for data and AI? – Y. Tolias
  • 15:30-16:30 VIEWPOINT 1
    Is eGFR the gold standard for evaluating renal dysfunction? Measuring GFR–tohubohu – E. Schaeffner (Germany)
    Estimating eGFR: no blind trust – P. Delanaye (Belgium)
  • 17:00-18:00 VIEWPOINT 2
    Quantitative mass spectrometry vs immunoassays of clinically relevant peptides and proteins Can quantitative mass spectrometry replace immunoassays for blood proteins? The only question is when? – C. Borchers (Canada)
    Quantitative mass spectrometry cannot replace immunossays for blood proteins – S. Lehmann (France)

DAY 3

Tuesday, 30 November

  • 9:00-10:00 PLENARY LECTURE
    Chair: K. Lackner (Germany)
    Biomarkers for cardiovascular risk stratification – S. Blankenberg (Germany)
  • 10:00-10:30 Break
  • 10:30-12:30 SYMPOSIUM 7
    Implementation of Liquid Biopsy
    Chairs: M. Neumaier (Germany), V. Haselmann (Germany)
    The European Liquid Biopsy Society – K. Pantel (Germany)
    Latest development in Liquid Profiling – N. Papadopoulos
    HTA of clinical decision-making of circulating nucleic acids in cancer patients – M. IJzerman (Australia)
    Topology identification of metastases based on ctDNA – Speaker to be announced
  • 10:30-12:30 SYMPOSIUM 8
    New approaches for determining reference intervals across all ages – Chairs: Y. Ozarda (Turkey), T. Streichert (Germany)
    Comparison of different approaches for deriving reference intervals – Y. Ozarda (Turkey)
    Age related RIs: Methods for continuous RIs and possible applications – T. Streichert (Germany)
    A new computer-intensive approach for the indirect derivation of reference intervals – K. Ichihara (Japan)
    Two oral communications selected among participants’ abstracts
  • 10:30-12:30 SYMPOSIUM 9
    New insights in amyloidosis – Chairs: G. Palladini (Italy), S.O. Schönland (Germany)
    The clinical laboratory in the management of systemic amyloidosis: state of the art – G. Palladini (Italy)
    Genetics of the amyloidogenic plasma cell clone: impact on clinical management – S.O. Schönland (Germany)
    Assessment of MRD in AL amyloidosis – B. Paiva (Spain)
    Two oral communications selected among participants’ abstracts
  • 10:30-12:30 SYMPOSIUM 10
    How to make EQA fit for purpose? – Chairs: P. Meijer (Netherlands), C. Buchta (Austria)
    What are the fundamental aims of EQA? – C. Buchta (Austria)
    The role of EQA in quality assurance of the extra-analytical phase – J. Cadamuro (Austria)
    Patient results for “real-time” surveillance of pre-analytical and analytical stability – A.E. Solsvik (Norway)
    Two oral communications selected among participants’ abstracts
  • 10:30-12:30 SYMPOSIUM 11
    Hemostasis – Chairs: B. Lammle (Germany), A. Tripodi (Italy)
    Thrombin generation and its application in the clinical laboratory – A. Tripodi (Italy)
    Monitoring of novel therapies of hemophilia in the clinical laboratory – S. Kitchen (UK)
    Thrombotic thrombocytopenic purpura – from bench to bedside – K. Vanhoorelbeke (Belgium)
    Two oral communications selected among participants’ abstracts
  • 10:30-12:30 DGKL SYMPOSIUM
    Autoimmune disorders of coagulation – Chairs: K. Lackner (Germany), U. Sachs (Germany)
    How to Diagnose Immune Thrombocytopenia – U. Sachs (Germany)
    Pathophysiology and Diagnosis of Antiphospholipid Syndrome – N. Müller-Calleja (Germany)
    Acquired hemophilia – diagnosis and treatment – A. Tiede (Germany)
    Two oral communications selected among participants’ abstracts
  • 12:30-14:00 POSTER SESSION
  • 14:00-16:00 SYMPOSIUM 12
    New development in Diagnosis and therapy of dyslipidemia and CVD – Chairs: B. Nordestgaard (Denmark), A. von Eckardstein (Switzerland)
    Advances in lipid-lowering therapy through antibody-based and gene-silencing technologies – B. Nordestgaard (Denmark)
    Measuring atherogenic lipoproteins that address residual cardiovascular risk beyond LDL-c – M. Langlois (Belgium)
    The challenges of measuring apolipoprotein(a) and its relevance for patient management
    and patient outcome – C. Cobbaert (Netherlands)
    HDL-Quo vadis? – A. von Eckardstein (Switzerland)
  • 15:30-16:30 VIEWPOINT 3
    Biomarkers of alcohol abuse in clinical and forensic use – strengths and limitations Carbohydrate deficient transferrin as marker for alcoholism, its use in comparison with ‘old’ indirect biomarkers – JPM. Wielders
    “Ethylglucuronide (EtG) – the one and only (direct) marker of alcohol consumption?” – H. Andresen-Streichert
  • 17:00-18:00 VIEWPOINT 4
    Which future for HbA1c as biomarker of diabetes monitoring? – Chair: E. Kilpatrick (UK)
    HbA1c remains the gold standard – G. John (UK)
    The future belongs to Time in Range and continuous glucose monitoring indications – D. Leslie (UK)

DAY 4

Wednesday, 1 December

  • 9:00-10:00 PLENARY LECTURE
    Chair: M. Neumaier (Germany)
    Integrative Diagnostics as the Key Driver for Intelligent Systems in Medicine – S. Schönberg (Germany)
  • 10:00-10:30 Break
  • 10:30-12:30 SYMPOSIUM 13
    Porphyrias – integration of laboratory medicine and clinical care (A symposium in memorial of the 140 years anniversary of the birth of Hans Fischer) – Chairs: S. Sandberg (Norway), A.K. Aarsand (Norway)
    Hans Fischer and his role in developing the field of porphyria – S. Sandberg (Norway)
    Practical guidelines on how to diagnose the porphyrias – A.K. Aarsand (Norway)
    Regulation of the haem biosynthesis – J. Philips (USA)
    Newer treatment options for porphyria – J.-C. Deybach (France)
  • 10:30-12:30 SYMPOSIUM 14
    Advances in IQC tools and techniques – Chair: T. Badrick (Australia)
    How is conventional QC practised now and how can it be improved? – E. Kilpatrick (UK)
    The importance of demonstrating commutability of reference materials with IQC – V. Delatour (France)
    Patient Based Real Time QC – an introduction – T. Badrick (Australia)
    PBRTQC – implementing into routine practice – validation and simulation – A. Bietenbeck (Germany)
  • 10:30-12:30 SYMPOSIUM 15
    High-sensitivity troponins and beyond – Chairs: S. Wittfooth (Finland), R. Christenson (USA)
    Troponin fragments for better specificity? – S. Wittfooth (Finland)
    Analytical aspects of high-sensitivity troponin assays: Impact on Clinical Application – R. Christenson (USA)
    High-sensitivity troponins in clinical use – P. Collinson (UK)
    Two oral communications selected among participants’ abstracts
  • 10:30-12:30 SYMPOSIUM 16
    Health platforms of the future and clinical relevance of interoperability
    Chair: C. Cobbaert (Netherlands)Defining Interoperability in Healthcare with HL7-FHIR and understanding the potential transformation of pathology – G. Grieve (Australia)
    The value of interoperable communication of pathology requests and results – K. Sikaris (Australia)
    The Health Platforms of the future and their clinical value to consumers – to be announced
  • 10:30-12:30 SYMPOSIUM 17
    New trends in standardization – Chair: P. Gillery (France)
    Standardization of bone markers – E. Cavalier (Belgium)
    Standardization in fecal immuno-testing – S. Benton (UK)
    Traceability chains in Therapeutic drug monitoring: scope, limitations and state of the art – C. Seger (Switzerland)
    Standardization in glucose monitoring – G. Freckmann (Germany)
  • 10:30-12:30 DGKL SYMPOSIUM
    Personalised medicine in allergy diagnostics – Chair: H. Renz (Germany)
    Molecular Diagnosis and Digital Health for Precision Allergology – P. Matricardi (Germany)
    Asthma and COPD diagnostics – lessons learned from multi-centre big data analysis – H. Renz (Germany)
    The Janus-faced nature of viral infections in asthma – C. Skevaki (Gerrmany)
    Chip-based diagnosis for personalized treatment – K. Niespodziana (Austria)
  • 12:30-14:00 POSTER SESSION
  • 14:00-16:00 SYMPOSIUM 18
    Consequences of IVDR Regulations on Laboratory Medicine – Chairs: C. Cobbaert (Netherlands), P- Monaghan (UK)
    Consequences of the IVDR 2017/746 for Laboratory Professionals – C. Cobbaert (Netherlands)
    Consequences of the IVDR 2017/746 for the IVD-industry – O. Bisazza
    Consequences of the IVDR 2017/746 for Notified Bodies – A.F. Stange (Japan)
    Overview of the delegated and implementing acts and guidance documents prepared by the European Commission – O. Tkachenco
  • 15:30-16:30 VIEWPOINT 5
    What should be the lipid profile in the era of personalized cardiovascular risk assessment and treatment? – Chair: M. Langlois (Belgium)
    Measuring lipids including traditional risk factors is crucial for cardiovascular risk assessment and treatment – E. Stroes (Netherlands)
    Assessment of traditional risk factors including a non-fasting lipid profile is no longer the most rational approach for cardiovascular risk assessment and treatment – B. Nordestgaard (Denmark)
  • 17:00-18:00 VIEWPOINT 6
    Regulating direct-to-consumer testing 2.0: Protecting the consumer – Chair: B. Gouget (France)
    Opportunities for decentralized testing in modern healthcare and dangers vs benefits of DTC – J.H. Nichols (USA)
    Advocacy for appropriate regulation of biological tests sold directly to consumers – M. Vaubourdolle (France)

DAY 5

Thursday, 2 December

  • 9:00-10:00 PLENARY LECTURE
    Fine tuning of innate immunity – T. Chavakis (Germany)
  • 10:00-10:30 Break
  • 10:30-12:30 SYMPOSIUM 19
    New diagnostic approaches in Laboratory Medicine – Chairs: M. Plebani (Italy)
    Extracellular vesicles in clinical diagnostics – K. Witwer (USA)
    miRNA in clinical diagnostics – can artificial intelligence make the difference? – A. Keller (Germany)
    Wearable biosensors – W. Gao (USA)
    Two oral communications selected among participants’ abstracts
  • <10:30-12:30 SYMPOSIUM 20
    Autoimmune Encephalitis – Chair: A. Vincent (UK)
    Overview and pathophysiology – A. Vincent (UK)
    Autoimmune encephalopathies in Neurology – M. Gastaldi (Italy)
    Autoimmune encephalopathies in Psychiatry – L. Tebartz van Elst (Germany)
    Two oral communications selected among participants’ abstracts/li>
  • 10:30-12:30 SYMPOSIUM 21
    Urinalysis: a new look at old tests – Chair: J.. Delanghe (Belgium)
    Modern urine test strip technology – J. Delanghe (Belgium)
    Automated urinalysis – G. Previtali (Italy)
    The Revised European Urinalysis Guidelines – T. Kouri (Finland)
    Two oral communications selected among participants’ abstracts
  • 10:30-12:30 SYMPOSIUM 22
    Young Scientist Session – Chairs: S. Fares Taie (Argentina), R. Sierra Amor (Mexico)
    Motivation in the Clinical Laboratory – S. Fares Taie (Argentina)
    Time Management Tools for the Young Laboratory Professional – J. El-Khoury (USA)
    Career management for Young Laboratory Scientists – G. Sancesario (Italy)
    Conflict Management amongst Young Laboratory Scientists – A. Rampul (South Africa)
  • 10:30-12:30 SYMPOSIUM 23
    How does Point of Care Testing change the clinical pathways? – Chairs: A. Khan (USA), A. Stavelin (Norway)
    Point-of-care Testing: a win-win for all players – A. Khan (USA)
    Is internal (and external?) quality control necessary for POCT? – A. Stavelin (Norway)
    The role of POC-testing in the clinical pathway of diagnosing SARS-CoV-2 infection – M.C. Tollanes (Norway)
    Two oral communications selected among participants’ abstracts
  • 10:30-12:30 DGKL SYMPOSIUM
    Emerging infectious diseases – impact of laboratory diagnosis
    Infectious disease emergency preparedness and prevention – J. Vila (Spain)
    Direct viral and serologic diagnosis of SARS-CoV-2 in 30 EU countries and pitfalls – V. Corman (Germany)
    Infectious disease surveillance in Europe – Speaker to be announced
    Two Oral communications selected among participants’ abstracts
  • 12:30-13:30 CLOSING CEREMONY
    Closing remarks
    Welcome to Roma
    WorldLab-Euromedlab Roma 2023 – S. Bernardini, President of the congress